Trial Profile
A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Newron Pharmaceuticals
- 22 Apr 2013 New trial record